Katie L. Allen Ziegler

Author

Also Known As

Grace K. Dy, K Ziegler, K. L. Allen Ziegler, K. Ziegler, Katie L Allen Ziegler, Katie L. Allen Ziegler, Katie L. Ziegler, Katie Ziegler

Publications

865

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic in Arizona Mayo Clinic in Florida Mayo Clinic Roswell Park Comprehensive Cancer Center National Institutes of Health

About

Katie L. Allen Ziegler is an author at Mayo Clinic in Arizona specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	301
2	Health Sciences	3	3	72
3	Nursing	1	1	28
4	Public Health	1	1	28
5	Child Development	1	1	28

Katie L. Allen Ziegler

Publications

802

Citations

H-Index

Page 1

	Year	Citations
Newborn and carrier screening for spinal muscular atrophy Thomas W. Prior, Pamela J. Snyder, B Rink, American Journal of Medical Genetics Part A	2010	263
Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426 Alex A. Adjei, Sumithra J. Mandrekar, Grace K. Dy, Journal of Clinical Oncology	2009	97
Randomized Phase II Trial of Sulindac, Atorvastatin, and Prebiotic Dietary Fiber for Colorectal Cancer Chemoprevention Paul J. Limburg, Michelle R. Mahoney, Katie L. Allen Ziegler, Cancer Prevention Research	2011	70
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma S. John Weroha, Ann L. Oberg, Katie L. Allen Ziegler, Gynecologic Oncology Primary Peritoneal CarcinomaPhase Ii TrialMedicineCancer ManagementPathology	2011	65
A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E2 in Patients With Barrett's Esophagus Gary W. Falk, Navtej Buttar, Nathan R. Foster, Gastroenterology Prostaglandin E2EsophagusEsophageal CancerPharmacologyGastroenterology	2012	63
Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer Sumithra J. Mandrekar, Yingwei Qi, Shauna L. Hillman, Journal of Thoracic Oncology Advanced Lung DiseaseMedicineClinical TrialsCancer TreatmentOncology	2010	38
A Randomized Phase IIb Trial of <i>myo</i> -Inositol in Smokers with Bronchial Dysplasia Stephen Lam, Sumithra J. Mandrekar, Yaron Gesthalter, Cancer Prevention Research	2016	36
Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668 Joel M. Reid, Chad A. Walden, Rui Qin, Cancer Prevention Research Molecular PharmacologyOncologyPharmacokinetic ModelingChemoprevention StrategyPhase 0	2011	30
Genetic counseling for congenital heart disease – Practice resource of the National Society of Genetic Counselors Hannah E. Ison, Emily Griffin, A. Parrott, Journal of Genetic Counseling CounselingFamily MedicineHeart FailurePediatric Heart DiseaseGenetic Epidemiology	2021	28
A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. Julian R. Molina, Grace K. Dy, Nathan R. Foster, Journal of Clinical Oncology PathologyAdditive CytotoxicityPharmacotherapyOncologyMetronomic Therapy	2011	24

Page 1